Article
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
Gastroenterology - 1 Sept 2016
Gane Edward J, Schwabe Christian, Hyland Robert H, Yang Yin, Svarovskaia Evguenia, Stamm Luisa M, Brainard Diana M, McHutchison John G, Stedman Catherine A
Abstract excerpt
BACKGROUND & AIMS: We performed a phase 2 trial of the efficacy and safety of 4, 6, and 8 weeks of sofosbuvir, given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection. METHODS: We enrolled 161 treatment-naïve or previously treated patients infected with HCV genotypes 1 or 3 with or without compensated cirrhosis at 2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.